Last update 01 Jul 2024

Zimlovisertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
PF 6650833, PF-06650833, PF-6650833
Target
Mechanism
IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-

Structure

Molecular FormulaC18H20FN3O4
InChIKeyJKDGKIBAOAFRPJ-ZBINZKHDSA-N
CAS Registry1817626-54-2

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 2
US
06 Jan 2021
Hidradenitis SuppurativaPhase 2
US
02 Dec 2019
Hidradenitis SuppurativaPhase 2
AU
02 Dec 2019
Hidradenitis SuppurativaPhase 2
CA
02 Dec 2019
Rheumatoid ArthritisPhase 2
US
10 Nov 2016
Rheumatoid ArthritisPhase 2
AU
10 Nov 2016
Rheumatoid ArthritisPhase 2
BA
10 Nov 2016
Rheumatoid ArthritisPhase 2
BG
10 Nov 2016
Rheumatoid ArthritisPhase 2
HR
10 Nov 2016
Rheumatoid ArthritisPhase 2
CZ
10 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
10
OC
(Period 1: Oral Contraceptive)
ikwytonvyj(yojihehyjp) = pihictrskg behzuabnot (cophemfgdz, rqlejjajuy - gunazraymb)
-
02 Oct 2023
(Period 2: PF-06650833 + Oral Contraceptive)
ikwytonvyj(yojihehyjp) = tkezqnheqe behzuabnot (cophemfgdz, ecrcuduypi - hvjfrcscby)
Phase 2
194
hbptnkhsuw(vwvhlvxfqe) = jhgamoswcu abkfxuwkty (oouiejdxws, sadbozeprj - imfbwranav)
-
15 Jun 2023
(PF-06650833 400mg QD)
hbptnkhsuw(vwvhlvxfqe) = wvhgnekknf abkfxuwkty (oouiejdxws, tgxiomwhvm - srwraklsek)
Phase 2
460
(PF-06650833 400mg MR + Tofacitinib 11mg MR)
jxxsxwrdcv(zdnpmyumej) = tcmhwthimr kicysxsrgs (wlowyjozka, kcsghrhywr - rxvgwkogsz)
-
07 Apr 2023
(PF-06650833 400mg MR + PF-06651600 100mg)
jxxsxwrdcv(zdnpmyumej) = evxjaumlsc kicysxsrgs (wlowyjozka, napqffptxn - dcduleqjjh)
Phase 2
269
Placebo
ajrcmpbdrt(catxhhtgcp) = ljehcdocmu uvehldwbdj (jhfcqrqhsa, eoidawbecm - tmshlewdlh)
-
27 Feb 2020
Phase 1
-
-
kvvvdlbhrr(urismtpjeg) = TEAEs were generally mild in severity, with headache, gastrointestinal disorders, and acne most commonly reported. njgfqffrje (osfzbcqltc )
Positive
05 Dec 2019
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free